Filters
Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
---|---|---|---|
Invitae Multi-Cancer + RNA Panel Invitae United States | 143 | 63 |
|
Invitae Comprehensive Deafness Panel Invitae United States | 405 | 219 |
|
Noonan spectrum disorder Comprehensive panel HNL Genomics Connective Tissue Gene Tests United States | 31 | 25 |
|
Noonan spectrum disorder Deletion / Duplication panel HNL Genomics Connective Tissue Gene Tests United States | 31 | 25 |
|
Neurofibromatosis and related disorders Comprehensive panel HNL Genomics Connective Tissue Gene Tests United States | 3 | 6 |
|
Noonan spectrum disorder NGS panel HNL Genomics Connective Tissue Gene Tests United States | 31 | 25 |
|
Neurofibromatosis and related disorders NGS panel HNL Genomics Connective Tissue Gene Tests United States | 3 | 6 |
|
Neurofibromatosis and related disorders Deletion / Duplication panel HNL Genomics Connective Tissue Gene Tests United States | 3 | 6 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Neurofibromatosis, type 2, 101000, Autosomal dominant; NF2 (Neurofibromatosis type 2) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey | 1 | 1 |
|
Medical Genomics Laboratory Department of Genetics UAB United States | 9 | 1 |
|
Quantitative Genomic Medicine Laboratories, SL Spain | 184 | 162 |
|
Invitae United States | 409 | 164 |
|
Invitae United States | 160 | 62 |
|
Invitae 78 Gene Actionable Disorders Panel Invitae United States | 220 | 75 |
|
Variant Resolution Test for CustomNext-Cancer® (+RNAinsight®) Ambry Genetics United States | 147 | 18 |
|
Variant Resolution Test for BrainTumorNext® (+RNAinsight®) Ambry Genetics United States | 72 | 8 |
|
Variant Resolution Test for CancerNext-Expanded® (+RNAinsight®) Ambry Genetics United States | 95 | 71 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.